FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3125860343> ?p ?o ?g. }

• W3125860343 abstract "<h3>Introduction and Objectives</h3> The management of chronic obstructive pulmonary disease (COPD) exacerbations varies by region; in most countries, patients are hospitalized for serious or potentially life-threatening exacerbations only, while mild/moderate exacerbations are managed in general practice or outpatient settings. To determine whether regional differences had an impact on outcomes in the ETHOS study, we performed a post-hoc analysis of severe exacerbation rates in selected regions with similar management of COPD exacerbations. <h3>Methods</h3> ETHOS (NCT02465567) was a 52-week, randomized, double-blind study in patients with moderate-to-very severe COPD who had ≥1 moderate/severe exacerbation in the previous year. Patients received budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) 320/14.4/10µg or 160/14.4/10μg; glycopyrronium/formoterol fumarate dihydrate (GFF) MDI 14.4/10µg; or budesonide/formoterol fumarate dihydrate (BFF) MDI 320/10µg. All treatments were administered twice-daily via an Aerosphere inhaler. This post-hoc analysis assessed the annualized rate of severe exacerbations (a secondary endpoint) in a subgroup of 23 countries with similar patient care practices, including all patients from Europe, North America, South America, Australia, New Zealand, and South Africa. <h3>Results</h3> The country subgroup population (n=7922) was a subset of the modified intent-to-treat (mITT) population (n=8509). In the global mITT population, BGF MDI 320/14.4/10µg significantly reduced the severe exacerbation rate by 20% versus BFF MDI (rate ratio [RR] 0.80 [95% CI 0.66–0.97], p=0.0221) with a numerical improvement of 16% versus GFF MDI (RR 0.84 [0.69–1.03], p=0.0944). In the country subgroup, BGF MDI 320/14.4/10µg significantly reduced severe exacerbations by 23% versus BFF MDI (RR 0.77 [95% CI 0.62–0.96], unadjusted p=0.0194); and by 20% versus GFF MDI (RR 0.80 [0.64–0.99], unadjusted p=0.0438). BGF MDI 160/14.4/10µg numerically improved severe exacerbation rates versus BFF MDI and GFF MDI (table 1). <h3>Conclusions</h3> In the 52-week ETHOS study, BGF MDI 320/14.4/10µg reduced the rate of severe exacerbations versus both BFF MDI and GFF MDI in a subset of 23 countries with similar patient care practices. The consistent risk reductions in this subset compared with the overall population support the benefits of BGF MDI 320/14.4/10µg compared with dual therapies in reducing the rate of exacerbations that require management in a hospital setting. Please refer to page A239 for declarations of interest related to this abstract." @default.
• W3125860343 created "2021-02-01" @default.
• W3125860343 creator A5004903602 @default.
• W3125860343 creator A5010723719 @default.
• W3125860343 creator A5016268562 @default.
• W3125860343 creator A5020395774 @default.
• W3125860343 creator A5027975503 @default.
• W3125860343 creator A5028213024 @default.
• W3125860343 creator A5051089874 @default.
• W3125860343 creator A5068917661 @default.
• W3125860343 creator A5081573795 @default.
• W3125860343 date "2021-01-21" @default.
• W3125860343 modified "2023-09-28" @default.
• W3125860343 title "S22 Rate of severe COPD exacerbations with Budesonide/Glycopyrronium/Formoterol fumarate dihydrate metered dose inhaler (BGF MDI) versus dual therapies: a post-hoc subgroup analysis of the ETHOS trial" @default.
• W3125860343 doi "https://doi.org/10.1136/thorax-2020-btsabstracts.28" @default.
• W3125860343 hasPublicationYear "2021" @default.
• W3125860343 type Work @default.
• W3125860343 sameAs 3125860343 @default.
• W3125860343 citedByCount "0" @default.
• W3125860343 crossrefType "proceedings-article" @default.
• W3125860343 hasAuthorship W3125860343A5004903602 @default.
• W3125860343 hasAuthorship W3125860343A5010723719 @default.
• W3125860343 hasAuthorship W3125860343A5016268562 @default.
• W3125860343 hasAuthorship W3125860343A5020395774 @default.
• W3125860343 hasAuthorship W3125860343A5027975503 @default.
• W3125860343 hasAuthorship W3125860343A5028213024 @default.
• W3125860343 hasAuthorship W3125860343A5051089874 @default.
• W3125860343 hasAuthorship W3125860343A5068917661 @default.
• W3125860343 hasAuthorship W3125860343A5081573795 @default.
• W3125860343 hasConcept C126322002 @default.
• W3125860343 hasConcept C2776042228 @default.
• W3125860343 hasConcept C2776136866 @default.
• W3125860343 hasConcept C2776780178 @default.
• W3125860343 hasConcept C2777014857 @default.
• W3125860343 hasConcept C2777450039 @default.
• W3125860343 hasConcept C2779871671 @default.
• W3125860343 hasConcept C2780261241 @default.
• W3125860343 hasConcept C2780667556 @default.
• W3125860343 hasConcept C2908647359 @default.
• W3125860343 hasConcept C2909086917 @default.
• W3125860343 hasConcept C67761136 @default.
• W3125860343 hasConcept C71924100 @default.
• W3125860343 hasConcept C99454951 @default.
• W3125860343 hasConceptScore W3125860343C126322002 @default.
• W3125860343 hasConceptScore W3125860343C2776042228 @default.
• W3125860343 hasConceptScore W3125860343C2776136866 @default.
• W3125860343 hasConceptScore W3125860343C2776780178 @default.
• W3125860343 hasConceptScore W3125860343C2777014857 @default.
• W3125860343 hasConceptScore W3125860343C2777450039 @default.
• W3125860343 hasConceptScore W3125860343C2779871671 @default.
• W3125860343 hasConceptScore W3125860343C2780261241 @default.
• W3125860343 hasConceptScore W3125860343C2780667556 @default.
• W3125860343 hasConceptScore W3125860343C2908647359 @default.
• W3125860343 hasConceptScore W3125860343C2909086917 @default.
• W3125860343 hasConceptScore W3125860343C67761136 @default.
• W3125860343 hasConceptScore W3125860343C71924100 @default.
• W3125860343 hasConceptScore W3125860343C99454951 @default.
• W3125860343 hasLocation W31258603431 @default.
• W3125860343 hasOpenAccess W3125860343 @default.
• W3125860343 hasPrimaryLocation W31258603431 @default.
• W3125860343 hasRelatedWork W1701559121 @default.
• W3125860343 hasRelatedWork W1991813083 @default.
• W3125860343 hasRelatedWork W2080041490 @default.
• W3125860343 hasRelatedWork W2119027045 @default.
• W3125860343 hasRelatedWork W2130094601 @default.
• W3125860343 hasRelatedWork W2970814147 @default.
• W3125860343 hasRelatedWork W3125860343 @default.
• W3125860343 hasRelatedWork W3157124429 @default.
• W3125860343 hasRelatedWork W3207119992 @default.
• W3125860343 hasRelatedWork W4312687383 @default.
• W3125860343 isParatext "false" @default.
• W3125860343 isRetracted "false" @default.
• W3125860343 magId "3125860343" @default.
• W3125860343 workType "article" @default.